Ibrutinib linked to invasive fungal infections - CLL Support

CLL Support

22,871 members39,244 posts

Ibrutinib linked to invasive fungal infections

lankisterguy profile image
lankisterguyVolunteer
2 Replies

In the past Idelalisib (Zydelig) was found to increase the risk of Pneumocystis in previously untreated patients. Now Ibrutinib has also been linked, fortunately prophylaxis is available and risks may be evaluated based on CD-4 T-cell levels. Talk to your CLL specialist to make certain this has been thoroughly considered for you specific case.

-

By Neil Osterweil Publish date: March 7, 2018

Vitals FROM BLOOD

mdedge.com/hematologynews/n...

The tyrosine kinase inhibitor ibrutinib (Imbruvica) may be associated with early-onset invasive fungal infections (IFI) in patients with hematologic malignancies, investigators caution.

-

French investigators identified 33 cases of invasive fungal infections occurring among patients who had been treated with ibrutinib as monotherapy or in combination with other agents. Of the 33 cases, 27 were invasive aspergillosis, and 40% of these were localized in the central nervous system. The findings were published in the journal Blood.

-

“IFI tend to occur within the first months of treatment and are infrequent thereafter. Whilst it seems difficult at this point to advocate for systematic antifungal prophylaxis in all patients, an increased awareness about the potential risk of IFI after initiating ibrutinib is warranted, especially when other predisposing factors are associated,” wrote David Ghez, MD, PhD, and colleagues at the Gustave Roussy Institute in Villejuif and other centers in France.

-

Although ibrutinib, an inhibitor of Bruton’s tyrosine kinase, is generally considered to be less immunosuppressive than other therapies, it was associated with five cases of Pneumocystis jirovecii pneumonia in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib monotherapy in a 2016 report (Blood. 2016;128:1940-3). Of these five patients, four were treatment naive, suggesting that ibrutinib itself could increase risk for invasive opportunistic infections, Dr. Ghez and his colleagues noted.

-

If you are interested in reading more- see the box labeled "Related Posts" (top of right column on computer screens, way below on mobile devices).

Len

Written by
lankisterguy profile image
lankisterguy
Volunteer
To view profiles and participate in discussions please or .
Read more about...
2 Replies
Cllcanada profile image
CllcanadaTop Poster CURE Hero

Aspergillosis may be an issue too, but can't use antifungal prophelactic like voriconazole with Imbruvica (ibrutinib), since they are highly interactive...

~chris

Beattiem-UK profile image
Beattiem-UK in reply to Cllcanada

Is there anything we can do ourselves to minimise the risks of getting aspergillosis?

Not what you're looking for?

You may also like...

VACCINATIONS FOR PEOPLE WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL/SLL)

This pinned post replaces our earlier reference post about vaccinations for those with CLL/SLL. It...

YABTKi or Yet Another BTK inhibitor - the A to Z list of Bruton's Tyrosine Kinase Inhibitors for CLL following Ibrutinib's success

I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...

Newly diagnosed with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - CLL/SLL or just found us? This post is for you!

Welcome to the CLL Support community on HealthUnlocked, a very active community with over 22,000...

Recent Chest CT scan to check for SLL progression, June 7, 2024 (part 2 of 2 posts)

IMPRESSION- Compared to May 30, 2024 The following is the chest CT scan. I'd appreciate your...

Important SARS-CoV-2 and Covid-19 information for Chronic Lymphocytic Leukaemia/CLL patients

This post, prepared in collaboration with      @[52122] , draws together some earlier posts...